ZIM Labs shortlisted for CPhI Awards 2017
October 14, 2017 Spread the awareness:
ZIM Laboratories Limited has been shortlisted as a finalist in the category Patient Centricity in the CPhI Awards 2017. ZIM is amongst the few selected companies in the world to have been shortlisted for the award to be held in Frankfurt, Germany on October, 24th, 2017.
ZIM has earned this honour for its Thinoral Technology. These are Fast Dissolving Thin Films, an indigenously produced, non-invasive, non-sticky, high load capacity drug administrative platform. The innovation targets patient convenience and adherence and ZIM is amongst the only few global pioneers to have mastered this technology. In 2016, ZIM won the award for “Best Innovation Development of a Solid Dosage Form” by IPA for the same technology.
This year, ZIM will be amongst the top 250 dignitaries from the global pharma community to attend the CPhI Awards 2017 hosted by CPhI Worldwide, an established pharmaceutical event which organizes conferences, seminars and pharma community charity expeditions across global destinations for top buyers, sellers and niche from the pharma supply chain.
About ZIM Labs
ZIM Laboratories Limited is an innovative drug delivery solutions providing company targeting patient convenience and adherence. It uses proprietary technologies (modified release and taste masking), to develop and manufacture differentiated pharmaceutical products.
It is located in Nagpur, Central India and is EU-GMP, WHO-GMP Certified and ISO9001:2008 accredited company supported by an excellent team of professionals and state-of-the-art facility.
ZIM is engaged in the activities of research and development, manufacturing, distribution and marketing of oral solid dosage formulations and pre-formulations (PFI) covering tablets, capsules, dry syrups, pellets, granules and orally disintegrating strips (ODS). More information available on ZIM.